Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New

  Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the
         Jefferies 2013 Global Healthcare Conference in New York City

PR Newswire

SAN FRANCISCO, May 30, 2013

SAN FRANCISCO, May 30, 2013 /PRNewswire/ --Nektar Therapeutics' (Nasdaq:
NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to
present at the upcoming 2013 Jefferies Global Healthcare Conference in New
York at the Grand Hyatt Hotel on Tuesday, June 4, 2013 at 9:00 a.m. Eastern
time.

The presentation will be accessible via a Webcast through a link posted in the
Investor Relations, Events Calendar section of the Nektar website:
http://www.nektar.com. This Webcast will be available for replay until July 8,
2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has completed Phase 3 development as a once-daily, oral tablet for the
treatment of opioid-induced constipation. This agreement also includes
NKTR-119, an earlier stage development program that is a co-formulation of
naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic candidate for
chronic pain conditions, is in Phase 2 development in osteoarthritis patients
with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development
to treat acute pain is in Phase 1 clinical development. In oncology,
etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study
(the BEACON study) for the treatment of metastatic breast cancer and is also
in Phase 2 studies for the treatment of ovarian and colorectal cancers. In
anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer
Healthcare as an adjunctive treatment for intubated and mechanically
ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C and Amgen's Neulasta® for neutropenia. Additional
development-stage products that leverage Nektar's proprietary technology
platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program,
which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at http://www.nektar.com.

Contact:
Jennifer Ruddock/Nektar Therapeutics
(415) 482-5585

SOURCE Nektar Therapeutics

Website: http://www.nektar.com
 
Press spacebar to pause and continue. Press esc to stop.